William Sandborn

38PUBLICATIONS
106CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical genetics (excl. cancer genetics)Genetic immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Apr 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).

Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber

|Jan 12, 2024
Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1.

William J Sandborn, Bruce E Sands, Sharif Uddin

|Jan 08, 2024
Pangenome comparison of <i>Bacteroides fragilis</i> genomospecies unveil genetic diversity and ecological insights.

Renee E Oles, Marvic Carrillo Terrazas, Luke R Loomis

|Aug 28, 2023
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.

William J Sandborn, Jingjing Chen, Krisztina Kisfalvi

|Jan 20, 2023
A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy.

Aaron T Mayer, Derek R Holman, Anav Sood

|Apr 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.

Niels Vande Casteele, William J Sandborn, Brian G Feagan

Pageof 7

Frequent Collaborators

15 joint publications

Siddharth Singh

15 joint publications

Brian G Feagan

14 joint publications

Parambir S Dulai

10 joint publications

Silvio Danese